Whalesbook
Zydus Lifesciences reported a stronger-than-expected financial performance for the fourth quarter of fiscal year 2026 (4QFY26), exceeding revenue, EBITDA, and PAT expectations. This was largely due to robust sales in the United States and key emerging markets.
Despite a stable US market, sales in constant currency terms declined by 11% in the quarter. Zydus is actively shifting its US strategy to build a specialty franchise through 505b2 products and acquisitions, complementing its existing generic offerings. The company's stock traded around ₹1018.90 on May 19, 2026, with a market capitalization of approximately ₹1,02,530 crore.
Zydus Lifesciences pursues a dual growth strategy. Its domestic formulation segment is outperforming the industry, focusing on chronic therapies and expanding biosimilar offerings with launches like Nivolumab, Aflibercept, and Semaglutide. Emerging markets have also shown consistent year-on-year growth in FY26 through targeted strategies.
Beyond organic growth, Zydus announced on May 13, 2026, an agreement to acquire Assertio Holdings for $23.50 per share, totaling about $166.4 million. This acquisition, expected to close in Q2 2026, has board approval and does not require regulatory approvals or financing contingencies. This move highlights a strategy to expand its US footprint via M&A. The company's Price-to-Earnings (P/E) ratio is around 20.1x, consistent with its historical average.
While the US market is crucial, the 11% decline in constant currency sales in 4QFY26 indicates potential challenges. Diversifying into specialty products and successfully integrating acquisitions like Assertio Holdings are key to addressing market saturation and competition. Integration of Assertio presents execution risks that the market will watch closely.
Motilal Oswal has increased its earnings estimates, projecting 5% growth for FY27 and 4% for FY28, based on anticipated gains from limited-competition US products, strong domestic and emerging market performance, and enhanced marketing efforts. The valuation of 21 times 12-month forward earnings supports the Rs 1,080 target price. A Board Meeting was scheduled for May 19, 2026, to discuss audited results, dividends, and buybacks. The successful integration of Assertio is expected to strengthen Zydus Lifesciences' US market position.